Versatile prostate cancer treatment with inducible caspase and interleukin-12

Area of Science:

• Oncology
• Immunology
• Gene Therapy

Background:

• Prostate cancer remains a significant health concern, necessitating novel therapeutic strategies.
• Developing effective immunotherapies requires optimizing antigen presentation and immune stimulation.

Purpose of the Study:

• To compare the efficacy of various immunotherapy approaches against prostate cancer in preclinical models.
• To identify optimal conditions for inducing robust antitumor immunity.

Main Methods:

• Utilized transgenic adenocarcinoma of the mouse prostate (TRAMP) models for autochthonous and subcutaneous tumors.
• Administered vaccines including apoptotic/necrotic tumor cells, dendritic cells, and adenoviruses expressing IL-12, B7-1, and caspase-1.
• Investigated different delivery methods, including nanopump-regulated viral delivery and intraprostatic administration.

Main Results:

• Interleukin-12 (IL-12)-containing apoptotic tumor cell vaccines conferred resistance to tumor challenge, irrespective of vaccination route.
• Adenovirus co-expressing B7-1 and IL-12 significantly protected against tumor growth and extended survival.
• Dendritic cell vaccines demonstrated comparable efficacy to IL-12-based vaccines.
• Ligand-inducible caspase-1 and IL-12 adenoviruses, particularly via nanopump delivery, eradicated larger tumors and induced local cell death.

Conclusions:

• Apoptosis induction via caspase in situ combined with IL-12 is a potent strategy against prostate cancer in a preclinical setting.
• Multifaceted immune activation involving CD4+, CD8+, and NK cells is crucial for effective antitumor responses.
• Optimized delivery systems and combination therapies hold promise for enhancing prostate cancer immunotherapy.